Clinical Trial Update: A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study of GSK2618960 in healthy volunteers and relapsing-remitting multiple sclerosis patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GSK2618960 (GSK2618960)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 1 | Status: TERMINATED